-
1.发明授权公开(公告)号：US09023799B2
公开(公告)日：2015-05-05
申请号：US11720983
申请日：2005-12-06
CPC分类号： A61K38/18
摘要： A method to treat the chronic stage of heart injury after ischemia or reperfusion by administering Midkine to a subject in need of such treatment is described.
摘要翻译： 描述了通过向需要这种治疗的受试者施用Midkine来治疗缺血或再灌注后心脏损伤的慢性期的方法。
-
2.发明申请公开(公告)号：US20100056437A1
公开(公告)日：2010-03-04
申请号：US11720983
申请日：2005-12-06
IPC分类号： A61K38/16
CPC分类号： A61K38/18
摘要： The present inventors compared myocardial damages after ischemia/reperfusion in wild-type mice and Midkine (MK)-deficient mice to confirm the effects and functions of MK. MK administration was found to significantly prevent cardiomyocyte apoptosis in both cultured cardiomyocytes (in vitro) and mouse models (in vivo).
摘要翻译： 本发明人比较野生型小鼠和Midkine（MK）缺陷小鼠缺血/再灌注后的心肌损伤，以证实MK的作用和功能。 发现MK给药在培养的心肌细胞（体外）和小鼠模型（体内）中显着预防心肌细胞凋亡。
-
公开(公告)号：US20100197577A1
公开(公告)日：2010-08-05
申请号：US12593277
申请日：2008-03-28
申请人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
发明人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
CPC分类号： C07K14/475 , A61K38/00
摘要： The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.
摘要翻译： 目的是找到一氧化氮合酶激活剂，给予激活剂的方法和待施用的活化剂的量。 公开了包含中期因子家族蛋白或中期因子衍生物作为活性成分的一氧化氮合酶激活剂。 具体公开了旨在通过血液，冠状动脉或静脉施用的一氧化氮合酶激活剂，其包含中期因子家族蛋白或中期因子衍生物作为活性成分。
-
4.发明授权Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation 有权通过中期因子激活内皮一氧化氮合酶，并用于实现血管舒张公开(公告)号：US08288343B2
公开(公告)日：2012-10-16
申请号：US12593277
申请日：2008-03-28
申请人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
发明人： Mitsuru Horiba , Kenji Kadomatsu , Itsuo Kodama , Takashi Muramatsu , Hisaaki Ishiguro , Hiroharu Takenaka , Arihiro Sumida
CPC分类号： C07K14/475 , A61K38/00
摘要： The object is to find a nitric oxide synthase activator, a method for the administration of the activator, and the amount of the activator to be administered. Disclosed is a nitric oxide synthase activator comprising a midkine family protein or a midkine derivative as an active ingredient. Specifically disclosed is a nitric oxide synthase activator which is intended to be administered through the blood, a coronary artery or a vein and which comprises a midkine family protein or a midkine derivative as an active ingredient.
摘要翻译： 目的是找到一氧化氮合酶激活剂，给予激活剂的方法和待施用的活化剂的量。 公开了包含中期因子家族蛋白或中期因子衍生物作为活性成分的一氧化氮合酶激活剂。 具体公开了旨在通过血液，冠状动脉或静脉施用的一氧化氮合酶激活剂，其包含中期因子家族蛋白或中期因子衍生物作为活性成分。
-
5.发明授权Pharmaceutical compositions for the prevention and treatment of atherosclerosis and restenosis after PTCA 有权用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物公开(公告)号：US07309695B2
公开(公告)日：2007-12-18
申请号：US10703783
申请日：2003-11-06
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
公开(公告)号：US07820160B2
公开(公告)日：2010-10-26
申请号：US11936438
申请日：2007-11-07
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
7.发明申请Pharmaceutical Compositions for the Prevention and Treatment of Atherosclerosis and Restenosis After PTCA 有权用于预防和治疗PTCA后的动脉粥样硬化和再狭窄的药物组合物公开(公告)号：US20080107659A1
公开(公告)日：2008-05-08
申请号：US11936438
申请日：2007-11-07
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C12N15/1136 , A61K2039/505 , C07K14/475 , C07K16/22 , C12N15/1137 , C12N15/1138
摘要： The present invention provides a pharmaceutical composition for the prevention or treatment of angiostenosis, comprising a compound inhibiting the function of midkine (MK) in blood vessel tissues as an effective ingredient. The present invention is useful for the prevention or treatment of angiostenosis attributed to arteriosclerosis or restenosis after percutaneous transluminal coronary angioplasty (PTCA). As compounds inhibiting the function of MK, antisense oligonucleotides that bind to a segment of a single-stranded mRNA transcribed from the MK gene to inhibit the synthesis of MK protein in cells, antibodies against the MK protein, and such can be used.
摘要翻译： 本发明提供了一种用于预防或治疗血管狭窄症的药物组合物，其包含抑制血管组织中的中期因子（MK）作为有效成分的功能的化合物。 本发明可用于预防或治疗经皮腔内冠状动脉血管成形术（PTCA）后动脉硬化或再狭窄引起的血管狭窄。 作为抑制MK功能的化合物，可以使用结合从MK基因转录的单链mRNA片段抑制细胞中MK蛋白合成的抗体的反义寡核苷酸等。
-
公开(公告)号：US20050079151A1
公开(公告)日：2005-04-14
申请号：US10641728
申请日：2003-08-15
申请人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
发明人： Shinya Ikematsu , Yoshihiro Yoshida , Kenji Kadomatsu , Munehiro Oda , Sadatoshi Sakuma , Kin-ya Ashida , Kohsuke Kino , Takashi Muramatsu
CPC分类号： A61K38/18
摘要： Proteins belonging to the MK family can suppress apoptosis induced by various stimuli such as carcinostatics, ultraviolet light and radiation, ischemic stresses, etc. Based on this finding, the invention provides novel agents for treating or preventing various diseases attributed to apoptosis such as cerebropathy, cardiopathy, nephropathy, neuropathy, or hepatopathy, etc., comprising proteins belonging to the MK family as an effective ingredient.
摘要翻译： 属于MK家族的蛋白质可以抑制由诸如制癌学，紫外光和辐射，缺血应激等各种刺激物诱导的凋亡。基于这一发现，本发明提供了用于治疗或预防由细胞凋亡引起的各种疾病如脑病， 心脏病，肾病，神经病或肝病等，其包含属于MK家族的蛋白质作为有效成分。
-
公开(公告)号：US20110125075A1
公开(公告)日：2011-05-26
申请号：US11988832
申请日：2006-07-14
IPC分类号： A61N1/30 , A01K67/027 , C12Q1/02
CPC分类号： A61N1/327 , A61K31/7088 , A61K38/1866 , A61K48/00 , A61N1/0424 , C12N15/111 , C12N15/1136 , C12N2310/14 , C12N2320/32 , C12N2320/51 , G01N33/5088
摘要： A method for controlling an electroporation apparatus for use in an animal such as human and a non-human animal, the method comprising a step of applying a voltage to an electrode of the electroporation apparatus placed in/on a biological sample of the animal in the presence of a nucleic acid construct capable of inhibiting the expression of a gene in the animal. In this manner, a nucleic acid construct can be introduced into a cell of a living body with good efficiency.
摘要翻译： 一种用于控制动物如人和非人动物的电穿孔装置的方法，所述方法包括向放置在动物生物样品中的电穿孔装置的电极施加电压的步骤 能够抑制动物中基因表达的核酸构建体的存在。 以这种方式，可以以高效率将核酸构建体引入生物体的细胞。
-
10.发明授权Polypeptide of N-acetylglucosamine-6-O-sulfotransferase and DNA encoding the same 有权N-乙酰葡糖胺-6-O-磺基转移酶的多肽和编码它们的DNA
公开(公告)号：US6037159A
公开(公告)日：2000-03-14
申请号：US263023
申请日：1999-03-05
申请人： Kenji Uchimura , Hideki Muramatsu , Kenji Kadomatsu , Reiji Kannagi , Osami Habuchi , Takashi Muramatsu
发明人： Kenji Uchimura , Hideki Muramatsu , Kenji Kadomatsu , Reiji Kannagi , Osami Habuchi , Takashi Muramatsu
CPC分类号： C07K16/2896 , C07K16/44 , C12N9/13 , C12P19/04
摘要： Apolypeptide of N-acetylglucosamine-6-O-sulfotransferase and a DNA encoding the peptide are provided. The polypeptide is (a) or (b) below:(a) a polypeptide consisting of an amino acid sequence represented by SEQ ID NO: 2; or(b) a polypeptide which comprises an amino acid sequence including substitution, deletion, insertion or transposition of one or few amino acids in the amino acid sequence of (a) and which has an enzymatic activity to transfer a sulfate group from a sulfate group donor to a hydroxyl group at 6 position of an N-acetylglucosamine residue located at a non-reducing end of an oligosaccharide represented by the formula I:GlcNAc.beta.1-3Gal.beta.1-4GlcNAc (I) wherein GlcNAc represents an N-acetylglucosamine residue, Gal represents a galactose residue, .beta.1-3 represents a .beta.1-3 glycosidic linkage, and .beta.1-4 represents a .beta.1-4 glycosidic linkage.
摘要翻译： 提供N-乙酰氨基葡萄糖-6-O-磺基转移酶的多肽和编码该肽的DNA。 多肽为（a）或（b）：（a）由SEQ ID NO：2所示的氨基酸序列组成的多肽; 或（b）包含在（a）的氨基酸序列中包含一个或几个氨基酸的取代，缺失，插入或转座的氨基酸序列的多肽，其具有从硫酸基团转移硫酸基团的酶活性 供体位于位于由式I表示的寡糖的非还原性末端的N-乙酰葡糖胺残基的6位的羟基：GlcNAcβ1〜3Galβ1-4GlcNAc（I），其中GlcNAc表示N-乙酰氨基葡萄糖残基 Gal代表半乳糖残基，β1-3代表β1-3糖苷键，β1-4代表β1-4糖苷键。
-
-
-
-
-
-
-
-
-
搜索结果
44 条记录 (耗时 0.02 秒)
